면역학 바이오시밀러 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of immunology biosimilars Market

The global immunology biosimilars market size was valued at USD 15.80 billion in 2025 and is projected to grow from USD 18.20 billion in 2026 to USD 38.25 billion by 2034, exhibiting a CAGR of 9.73% during the forecast period. Europe dominated the market with a 35.69% market share in 2025. The market comprises biosimilar therapies used for autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Increasing patent expirations of major biologics, regulatory approvals, growing physician confidence, and payer efforts to reduce treatment costs are supporting market growth. In March 2025, Celltrion launched STEQEYMA, an ustekinumab biosimilar to STELARA, in the U.S., expanding access to biosimilar treatment for several chronic inflammatory conditions.

Market Trends

Growing Shift Toward Affordable Immunology Biologics

Healthcare systems are increasingly adopting biosimilars to expand patient access while controlling the cost of long-term biologic treatment. The availability of multiple biosimilar options is increasing price competition and encouraging physicians and healthcare providers to consider switching from reference biologics. In January 2026, Biocon Biologics introduced three immunology biosimilar assets targeting trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, reflecting continued expansion of biosimilar portfolios.

Market Dynamics

Driver - Growing Patent Expirations and Regulatory Approvals

The loss of exclusivity for major immunology biologics is creating opportunities for biosimilar manufacturers. Products targeting established molecules such as adalimumab, infliximab, etanercept, and ustekinumab are expanding treatment options and competition. Increasing regulatory approvals are also allowing manufacturers to commercialize biosimilars across multiple indications.

Restraint - Intense Price Competition

Mature biosimilar molecules face competition from several products targeting the same reference biologic. Manufacturers often compete through discounts, rebates, hospital tenders, and formulary agreements. At the same time, biosimilar production requires complex manufacturing, quality testing, regulatory compliance, and pharmacovigilance, creating pressure on margins and commercial sustainability.

Market Opportunity - Next-Wave Immunology Molecules

Manufacturers are increasingly targeting newer biologics and expanding into indications such as allergic asthma, chronic spontaneous urticaria, nasal polyps, inflammatory bowel disease, and juvenile arthritis. These opportunities can allow companies to diversify beyond highly competitive mature molecules and expand their addressable patient population.

Market Challenge - Regulatory and Development Complexity

Biosimilar developers must demonstrate extensive analytical comparability, pharmacokinetic characteristics, immunogenicity, safety, and manufacturing consistency. Different regulatory requirements across countries can increase development costs and extend approval timelines, particularly for complex monoclonal antibodies and next-generation immunology products.

Segmentation Analysis

By Drug Class

The market is segmented into TNF-alpha inhibitors, interleukin inhibitors, B-cell/anti-CD20 therapies, anti-IgE therapies, and others. TNF-alpha inhibitors dominated in 2025, supported by broad use of adalimumab, infliximab, and etanercept across autoimmune diseases and extensive physician familiarity. Anti-IgE therapies are projected to grow at a CAGR of 16.61%.

By Product

The market includes adalimumab, infliximab, etanercept, rituximab, ustekinumab, tocilizumab, omalizumab, golimumab, and other biosimilars. Infliximab biosimilars held the leading position in 2025, supported by extensive clinical use and established physician confidence. Ustekinumab biosimilars are projected to grow at a CAGR of 23.24%.

By Indication

Rheumatology, gastroenterology, dermatology, allergy and clinical immunology, systemic autoimmune diseases and vasculitis, ophthalmic immunology, and others constitute the segments. Rheumatology dominated in 2025, driven by long-term treatment requirements for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory joint disorders. Allergy and clinical immunology is projected to grow at a CAGR of 16.22%.

By Age Group

The market is divided into pediatric and adult. Adults dominated in 2025, reflecting the large population affected by chronic autoimmune and inflammatory conditions requiring long-term biologic treatment. The pediatric segment is projected to grow at a CAGR of 12.73%.

By Route of Administration

Subcutaneous, intravenous, and other routes are covered. Subcutaneous products dominated in 2025, owing to greater convenience and reduced infusion requirements for long-term treatment. The others segment is projected to grow at a CAGR of 8.64%.

By Distribution Channel

The market includes hospital pharmacies, specialty pharmacies, drug stores and retail pharmacies, and online pharmacies. Hospital pharmacies dominated in 2025, supported by institutional procurement, specialist-led treatment, cold-chain requirements, and centralized biosimilar purchasing. Specialty pharmacies are projected to grow at a CAGR of 12.57%.

Regional Outlook

Europe

Europe dominated the market in 2025 with a market value of USD 5.64 billion and is projected to reach USD 6.31 billion in 2026. Established biosimilar regulations, centralized tendering, physician experience, and healthcare-system efforts to reduce biologic expenditure support regional growth. Germany is projected to reach USD 1.36 billion in 2026, while the U.K. is estimated at USD 0.87 billion.

North America

North America reached USD 4.81 billion in 2025, compared with USD 4.08 billion in 2024. Biosimilar launches, biologic patent expirations, payer pressure, and expanding interchangeability designations are supporting adoption. The U.S. market is estimated at USD 5.13 billion in 2026.

Asia Pacific

Asia Pacific held the third-largest position in 2025 and is projected to reach USD 4.94 billion in 2026. China, Japan, India, and other regional markets benefit from large patient populations, improving biologic access, and expanding biosimilar manufacturing. Japan is estimated at USD 1.04 billion, China at USD 1.17 billion, and India at USD 0.85 billion in 2026.

Latin America and Middle East & Africa

Latin America is estimated to reach USD 0.81 billion in 2026, supported by regulatory approvals and commercialization partnerships. The GCC market is projected to reach USD 0.23 billion, while South Africa is estimated at approximately USD 0.12 billion in 2026.

Competitive Landscape

Key companies include Celltrion, Sandoz, Samsung Bioepis, Biogen, Organon, Amgen, Pfizer, Fresenius Kabi, Biocon Biologics, Alvotech, and STADA Arzneimittel. Companies are focusing on new product launches, regulatory approvals, interchangeability designations, strategic partnerships, manufacturing expansion, and geographic commercialization.

Key Industry Developments

In February 2026, STADA and Bio-Thera Solutions received European Commission marketing authorization for Gotenfia, a golimumab biosimilar. In November 2025, Celltrion received European Commission authorization for the liquid formulation of Remsima IV. In November 2025, Bio-Thera Solutions entered an agreement with Dr. Reddy's Laboratories for a proposed secukinumab biosimilar. In August 2025, Gedeon Richter received European authorization for BAT2206, an ustekinumab biosimilar. In August 2025, Bio-Thera and STADA expanded their biosimilar alliance to include tocilizumab.

Report Coverage

The Immunology Biosimilars Market Report provides comprehensive Market Research Report coverage of market size, market value, Market Share, Market Trends, Market Growth, Market Analysis, Industry Analysis, Market Forecast, regional performance, segmentation, regulatory developments, product launches, pricing dynamics, competitive strategies, partnerships, and acquisitions. The Industry Report evaluates drug class, product, indication, age group, route of administration, and distribution channel while analyzing Market Opportunities and challenges through 2034.

Conclusion

The global immunology biosimilars market is expanding as healthcare systems seek affordable alternatives to high-cost biologic therapies and pharmaceutical companies respond to growing patent expirations. The market size is projected to increase from USD 15.80 billion in 2025 to USD 18.20 billion in 2026 and USD 38.25 billion by 2034. TNF-alpha inhibitors, infliximab biosimilars, rheumatology, adult therapies, subcutaneous products, and hospital pharmacies remain important market segments. Meanwhile, ustekinumab and anti-IgE biosimilars, emerging immunology molecules, expanding interchangeability, and growing adoption in Asia Pacific are creating additional Market Opportunities. Price competition, regulatory complexity, manufacturing requirements, and market-access barriers will continue to influence the Market Outlook through 2034.

Segmentation By Drug Class, Product, Indication, Age Group, Route of Administration, Distribution Channel, and Region

By Drug Class

• TNF-alpha Inhibitors
• Interleukin Inhibitors
• B-cell/Anti-CD20 Therapies
• Anti-IgE Therapies
• Others

By Product

• Adalimumab Biosimilars
• Infliximab Biosimilars
• Etanercept Biosimilars
• Rituximab Biosimilars
• Ustekinumab Biosimilars
• Tocilizumab Biosimilars
• Omalizumab Biosimilars
• Golimumab Biosimilars
• Others

By Indication

• Rheumatology
• Gastroenterology
• Dermatology
• Allergy & Clinical Immunology
• Systemic Autoimmune Diseases & Vasculitis
• Ophthalmic Immunology
• Others

By Age Group

• Pediatric
• Adults

By Route of Administration

• Subcutaneous
• Intravenous
• Others

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug Class, Product, Indication, Age Group, Route of Administration, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Drug Class, Product, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Product, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Product, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Product, Indication, Age Group, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Disease Indications, By Key Regions, Countries
• 4.2. Pipeline Analysis, By Key Regions
• 4.3. Overview of Regulatory Scenario, By Key Regions/Countries
• 4.4. New Product Launches, By Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Immunology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. TNF-alpha Inhibitors
  • 5.1.2. Interleukin Inhibitors
  • 5.1.3. B-cell/Anti-CD20 Therapies
  • 5.1.4. Anti-IgE Therapies
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. Adalimumab Biosimilars
  • 5.2.2. Infliximab Biosimilars
  • 5.2.3. Etanercept Biosimilars
  • 5.2.4. Rituximab Biosimilars
  • 5.2.5. Ustekinumab Biosimilars
  • 5.2.6. Tocilizumab Biosimilars
  • 5.2.7. Omalizumab Biosimilars
  • 5.2.8. Golimumab Biosimilars
  • 5.2.9. Others
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Rheumatology
  • 5.3.2. Gastroenterology
  • 5.3.3. Dermatology
  • 5.3.4. Allergy & Clinical Immunology
  • 5.3.5. Systemic Autoimmune Diseases & Vasculitis
  • 5.3.6. Ophthalmic Immunology
  • 5.3.7. Others
• 5.4. Market Analysis, Insights and Forecast - By Age Group
  • 5.4.1. Pediatric
  • 5.4.2. Adults
• 5.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.5.1. Subcutaneous
  • 5.5.2. Intravenous
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.6.1. Hospital Pharmacies
  • 5.6.2. Specialty Pharmacies
  • 5.6.3. Drug Stores & Retail Pharmacies
  • 5.6.4. Online Pharmacies
• 5.7. Market Analysis, Insights and Forecast - Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America Immunology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. TNF-alpha Inhibitors
  • 6.1.2. Interleukin Inhibitors
  • 6.1.3. B-cell/Anti-CD20 Therapies
  • 6.1.4. Anti-IgE Therapies
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. Adalimumab Biosimilars
  • 6.2.2. Infliximab Biosimilars
  • 6.2.3. Etanercept Biosimilars
  • 6.2.4. Rituximab Biosimilars
  • 6.2.5. Ustekinumab Biosimilars
  • 6.2.6. Tocilizumab Biosimilars
  • 6.2.7. Omalizumab Biosimilars
  • 6.2.8. Golimumab Biosimilars
  • 6.2.9. Others
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Rheumatology
  • 6.3.2. Gastroenterology
  • 6.3.3. Dermatology
  • 6.3.4. Allergy & Clinical Immunology
  • 6.3.5. Systemic Autoimmune Diseases & Vasculitis
  • 6.3.6. Ophthalmic Immunology
  • 6.3.7. Others
• 6.4. Market Analysis, Insights and Forecast - By Age Group
  • 6.4.1. Pediatric
  • 6.4.2. Adults
• 6.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.5.1. Subcutaneous
  • 6.5.2. Intravenous
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.6.1. Hospital Pharmacies
  • 6.6.2. Specialty Pharmacies
  • 6.6.3. Drug Stores & Retail Pharmacies
  • 6.6.4. Online Pharmacies
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
  • 6.7.2. Canada

7. Europe Immunology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. TNF-alpha Inhibitors
  • 7.1.2. Interleukin Inhibitors
  • 7.1.3. B-cell/Anti-CD20 Therapies
  • 7.1.4. Anti-IgE Therapies
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. Adalimumab Biosimilars
  • 7.2.2. Infliximab Biosimilars
  • 7.2.3. Etanercept Biosimilars
  • 7.2.4. Rituximab Biosimilars
  • 7.2.5. Ustekinumab Biosimilars
  • 7.2.6. Tocilizumab Biosimilars
  • 7.2.7. Omalizumab Biosimilars
  • 7.2.8. Golimumab Biosimilars
  • 7.2.9. Others
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Rheumatology
  • 7.3.2. Gastroenterology
  • 7.3.3. Dermatology
  • 7.3.4. Allergy & Clinical Immunology
  • 7.3.5. Systemic Autoimmune Diseases & Vasculitis
  • 7.3.6. Ophthalmic Immunology
  • 7.3.7. Others
• 7.4. Market Analysis, Insights and Forecast - By Age Group
  • 7.4.1. Pediatric
  • 7.4.2. Adults
• 7.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.5.1. Subcutaneous
  • 7.5.2. Intravenous
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.6.1. Hospital Pharmacies
  • 7.6.2. Specialty Pharmacies
  • 7.6.3. Drug Stores & Retail Pharmacies
  • 7.6.4. Online Pharmacies
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. U.K.
  • 7.7.2. Germany
  • 7.7.3. France
  • 7.7.4. Italy
  • 7.7.5. Spain
  • 7.7.6. Scandinavia
  • 7.7.7. Rest of Europe

8. Asia Pacific Immunology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. TNF-alpha Inhibitors
  • 8.1.2. Interleukin Inhibitors
  • 8.1.3. B-cell/Anti-CD20 Therapies
  • 8.1.4. Anti-IgE Therapies
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. Adalimumab Biosimilars
  • 8.2.2. Infliximab Biosimilars
  • 8.2.3. Etanercept Biosimilars
  • 8.2.4. Rituximab Biosimilars
  • 8.2.5. Ustekinumab Biosimilars
  • 8.2.6. Tocilizumab Biosimilars
  • 8.2.7. Omalizumab Biosimilars
  • 8.2.8. Golimumab Biosimilars
  • 8.2.9. Others
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Rheumatology
  • 8.3.2. Gastroenterology
  • 8.3.3. Dermatology
  • 8.3.4. Allergy & Clinical Immunology
  • 8.3.5. Systemic Autoimmune Diseases & Vasculitis
  • 8.3.6. Ophthalmic Immunology
  • 8.3.7. Others
• 8.4. Market Analysis, Insights and Forecast - By Age Group
  • 8.4.1. Pediatric
  • 8.4.2. Adults
• 8.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.5.1. Subcutaneous
  • 8.5.2. Intravenous
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.6.1. Hospital Pharmacies
  • 8.6.2. Specialty Pharmacies
  • 8.6.3. Drug Stores & Retail Pharmacies
  • 8.6.4. Online Pharmacies
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
  • 8.7.2. Japan
  • 8.7.3. India
  • 8.7.4. Southeast Asia
  • 8.7.5. Australia
  • 8.7.6. Rest of Asia Pacific

9. Latin America Immunology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. TNF-alpha Inhibitors
  • 9.1.2. Interleukin Inhibitors
  • 9.1.3. B-cell/Anti-CD20 Therapies
  • 9.1.4. Anti-IgE Therapies
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. Adalimumab Biosimilars
  • 9.2.2. Infliximab Biosimilars
  • 9.2.3. Etanercept Biosimilars
  • 9.2.4. Rituximab Biosimilars
  • 9.2.5. Ustekinumab Biosimilars
  • 9.2.6. Tocilizumab Biosimilars
  • 9.2.7. Omalizumab Biosimilars
  • 9.2.8. Golimumab Biosimilars
  • 9.2.9. Others
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Rheumatology
  • 9.3.2. Gastroenterology
  • 9.3.3. Dermatology
  • 9.3.4. Allergy & Clinical Immunology
  • 9.3.5. Systemic Autoimmune Diseases & Vasculitis
  • 9.3.6. Ophthalmic Immunology
  • 9.3.7. Others
• 9.4. Market Analysis, Insights and Forecast - By Age Group
  • 9.4.1. Pediatric
  • 9.4.2. Adults
• 9.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.5.1. Subcutaneous
  • 9.5.2. Intravenous
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.6.1. Hospital Pharmacies
  • 9.6.2. Specialty Pharmacies
  • 9.6.3. Drug Stores & Retail Pharmacies
  • 9.6.4. Online Pharmacies
• 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.7.1. Brazil
  • 9.7.2. Mexico
  • 9.7.3. Rest of Latin America

10. Middle East & Africa Immunology Biosimilars Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. TNF-alpha Inhibitors
  • 10.1.2. Interleukin Inhibitors
  • 10.1.3. B-cell/Anti-CD20 Therapies
  • 10.1.4. Anti-IgE Therapies
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Product
  • 10.2.1. Adalimumab Biosimilars
  • 10.2.2. Infliximab Biosimilars
  • 10.2.3. Etanercept Biosimilars
  • 10.2.4. Rituximab Biosimilars
  • 10.2.5. Ustekinumab Biosimilars
  • 10.2.6. Tocilizumab Biosimilars
  • 10.2.7. Omalizumab Biosimilars
  • 10.2.8. Golimumab Biosimilars
  • 10.2.9. Others
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Rheumatology
  • 10.3.2. Gastroenterology
  • 10.3.3. Dermatology
  • 10.3.4. Allergy & Clinical Immunology
  • 10.3.5. Systemic Autoimmune Diseases & Vasculitis
  • 10.3.6. Ophthalmic Immunology
  • 10.3.7. Others
• 10.4. Market Analysis, Insights and Forecast - By Age Group
  • 10.4.1. Pediatric
  • 10.4.2. Adults
• 10.5. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.5.1. Subcutaneous
  • 10.5.2. Intravenous
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.6.1. Hospital Pharmacies
  • 10.6.2. Specialty Pharmacies
  • 10.6.3. Drug Stores & Retail Pharmacies
  • 10.6.4. Online Pharmacies
• 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.7.1. GCC
  • 10.7.2. South Africa
  • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Celltrion, Inc.
  • 11.2.2. Sandoz Group AG
  • 11.2.3. Samsung Bioepis Co., Ltd.
  • 11.2.4. Biogen Inc.
  • 11.2.5. Organon & Co.
  • 11.2.6. Amgen Inc.
  • 11.2.7. Pfizer Inc.
  • 11.2.8. Fresenius Kabi AG
  • 11.2.9. Biocon Biologics Ltd.
  • 11.2.10. Alvotech
  • 11.2.11. STADA Arzneimittel AG
  • 11.2.12. Teva Pharmaceutical Industries Ltd.
  • 11.2.13. Boehringer Ingelheim International GmbH
  • 11.2.14. Bio-Thera Solutions, Ltd.
  • 11.2.15. Innovent Biologics, Inc.
  • 11.2.16. Other approved manufacturers.